

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4048419

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	BRAIN CORPORATION	09/15/2014
RECEIVING PARTY DATA		
Name:	QUALCOMM TECHNOLOGIES, INC.	
Street Address:	5775 MOREHOUSE DRIVE	
City:	SAN DIEGO	
State/Country:	CALIFORNIA	
Postal Code:	92121	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15090487
CORRESPONDENCE DATA		
Fax Number:	(310)201-5219	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	310.277.7200	
Email:	Qualcomm-USPTO@seyfarth.com	
Correspondent Name:	SEYFARTH SHAW LLP	
Address Line 1:	2029 CENTURY PARK EAST, SUITE 3500	
Address Line 4:	LOS ANGELES, CALIFORNIA 90067	
ATTORNEY DOCKET NUMBER:	147495C1	
NAME OF SUBMITTER:	CORNELL D. CROSBY	
SIGNATURE:	/Cornell D. Crosby/	
DATE SIGNED:	09/12/2016	
Total Attachments: 5		
source=Assignment Brain Corp. to QTI#page1.tif		
source=Assignment Brain Corp. to QTI#page2.tif		
source=Assignment Brain Corp. to QTI#page3.tif		
source=Assignment Brain Corp. to QTI#page4.tif		
source=Assignment Brain Corp. to QTI#page5.tif		

Exhibit B
Assignment of Patent Rights

ASSIGNMENT

WHEREAS, Brain Corporation, a corporation organized under the laws of California, having a principal business address at 5665 Morehouse Drive, QRC 130J, San Diego, California 92121 (“**Assignor**”) and Qualcomm Technologies, Inc., a Delaware corporation, having a principal place of business located at 5775 Morehouse Drive, San Diego, California 92121, United States of America (“**Assignee**”) have entered into a Termination Agreement on or about September 15, 2014, (the “**Termination Agreement**”) wherein Assignor has agreed to assign and otherwise transfer to Assignee, and Assignee has agreed to receive or otherwise obtain from Assignor, the Assigned Patents (as that term is defined in the Termination Agreement).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

Assignor hereby irrevocably and unconditionally sells, assigns, transfers, and conveys to Assignee, and its successors and assigns of the Assigned Patents, effective as of the first conception, origination, creation, preparation or discovery of the inventions claimed in the Assigned Patents, all right, title, and interest in and to each patent and patent application listed on Attachment 1 attached hereto and all patents arising or issuing therefrom, together with all reissues, reexaminations, extensions, divisions, continuations, continuations-in-part and counterparts (whether domestic or foreign) of any such patents and patent applications, and all patents arising or issuing therefrom, and all claimed inventions in each of the foregoing items (collectively, the “**Assigned Patents**”).

The sale, assignment, transfer, and conveyance to Assignee, and its successors and assigns of the Assigned Patents, of each of the foregoing items also includes, without limitation, all past, present and future causes of action (whether known or unknown or whether currently pending, filed, or otherwise) and other enforcement rights, including any past, current, and future claims of infringement, relating to any of the items described in the preceding paragraph.

The foregoing sale, assignment, transfer and conveyance by Assignor of the Assigned Patents to Assignee, as documented in this assignment, is made subject to the nonexclusive license rights for the Assigned Patents retained by Assignor Seller in the Termination Agreement.

Assignor hereby represents to Assignee that Assignor has the right, power and authority to make the foregoing sale, assignment, transfer and conveyance of each of the foregoing items to Purchaser and its successors and assigns.

The terms and conditions of the assignment set forth above will inure to the benefit of Assignee and its successors and assigns of the Assigned Patents and other rights set forth above. Assignor hereby authorizes the respective patent office or governmental agency in each jurisdiction to issue any and all patents or certificates of invention which may be granted upon any of the Assigned Patents in the name of Assignee, as the assignee to the entire interest therein.

IN WITNESS WHEREOF, the duly authorized undersigned individual has caused this Assignment to be executed, on behalf of Assignor, on September 15, 2014.

Brain Corporation

By: Eugene Izhikovich

Printed Name: Eugene Izhikovich

Title: CEO

COUNTRY OF United States of America


CITY OF San Diego, CA

Before me on this 15 day of September, 2014, personally appeared Eugene M. Izhikovich personally known to me or proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument, and acknowledged to me that he/she executed the within instrument in his/her authorized capacity as CEO of Brain Corporation, a corporation organized under the laws of Delaware, and that he/she signed the within instrument of his/her own free will and for the purpose expressed therein.

WITNESS my hand and official seal:

Notary Public:

Teresa V. Allen



My commission expires: February 17, 2017

ACKNOWLEDGMENT

State of California

County of San Diego)


On September 15, 2014 before me, Teresa V. Allen, Notary Public
(insert name and title of the officer)

personally appeared Eugene M. Izhikevich,
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are
subscribed to the within instrument and acknowledged to me that he/she/they executed the same in
his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the
person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing
paragraph is true and correct.

WITNESS my hand and official seal.

Signature Teresa V. Allen (Seal)



PATENT

REEL: 039706 FRAME: 0704

Attachment 1
Patents and Patent Applications

Case Reference	Grant Number	Application Number	Publication Number	Country	Issue Date	Application Date
BC201216PR		61/671,434		US		7/13/2012
BC201216A	TBD	13/829,919	20140019392	US	TBD	3/14/2013
BC201216DV1		14/468,928		US		8/26/2014
BC201301A	TBD	13/774,934	N/A	US	TBD	2/22/2013
BC201301DV1		14/466,917	N/A	US		8/22/2014
BC201303A*	TBD	13/763,005	20140229411	US	TBD	2/8/2013
BC201107A		13/239,255	US20130073499	US	Pending	9/21/2011
BC201107VPC		PCT/US12/56389	WO2013043903	PCT		9/22/2012
BC201107VTW		101134775	201322150	TW		9/21/2012
BC201108A	8,725,662	13/239,259	US20130073491	US	5/13/2014	9/21/2011
BC201108C1		14/275,663	N/A	US		5/12/2014
BC201111A		13/239,123	US20130073495	US	Pending	9/21/2011
BC201111VPC		PCT/US2012/055933	WO2013043610A1	PCT		9/18/2012
BC201111VTW		101133859	201329743	TW		9/14/2012
BC201112A	8,712,941	13/239,148	US20130073498	US	4/29/2014	9/21/2011
BC201113A	8,725,658	13/239,155	US20130073484	US	5/13/2014	9/21/2011
BC201113C1		14/198,550	TBD	US		3/5/2014
BC201114A	8,719,199	13/239,163	US20130073492	US	5/6/2014	9/21/2011
BC201114C1		14/198,446	TBD	US		3/5/2014

BC201201A		13/385,933	US201300735 00	US		3/15/2012
BC201201D V1	8,712,9 39	13/385,938	US201300734 96	US	4/29/20 14	3/15/2012
BC201201D V2		13/385,937	TBD	US		3/15/2012
BC201201V PC		PCT/US13/32546	WO20131387 78 A1	PCT		3/15/2013
BC201220A		13/588,774	US201400526 79	US		8/17/2012
BC201220V PC		PCT/US2013/055 381	WO20140288 55 A1	PCT		8/16/2013
BC201221A		13/560,891	US201400324 58	US		7/27/2012
BC201221V PC		PCT/US13/52127	WO20140187 93 A1	PCT		7/25/2013
BC201237A		13/868,944	N/A	US		4/23/2013
BC201317A		13/875,225	N/A	US		5/1/2013
BC201318A		13/875,234	N/A	US		5/1/2013
BC201328A		14/020,376	N/A	US		9/6/2013
BC201230A		13/601,827	N/A	US		8/31/2012

* Notwithstanding the foregoing, provided that BC complies with the Reserved Application Scope Limits in the course of prosecution of the Reserved Application and any application deriving priority therefrom, Assigned Patents shall exclude the Reserved Application together with (i) any patent issuing on such patent application, (ii) any reissue, division, re-examination, renewal, extension, continuation, to any such patent application or patent, (iii) any patent or patent application that derives priority from such patent application.

35.

QTI and BC Proprietary and Confidential